ABBV-927 + carboplatin + ABBV-368

Combination therapy of **ABBV-927** (a monoclonal antibody targeting CD40), **carboplatin** (a platinum-based chemotherapy agent), and **ABBV-368** (a monoclonal antibody targeting OX40) is an investigational regimen for advanced solid tumors, including unresectable or metastatic cancers. **ABBV-927** acts as an immune agonist to stimulate T-cell activation, **carboplatin** induces DNA damage in cancer cells, and **ABBV-368** activates OX40-mediated T-cell responses, together aiming to synergistically enhance anti-tumor immunity. This combination is in early-phase studies for solid tumors such as metastatic pancreatic cancer.[1][3][5]